ESSA Pharma Inc. (NASDAQ:EPIX), a Canada-based pharmaceutical company, announced on Thursday that Nasdaq has set August 25, 2025, as the ex-dividend date for its previously disclosed USD80m return of capital distribution.

The payment, amounting to approximately USD1.69 per common share and subject to applicable withholding, will be made on August 22, 2025, to shareholders of record.

The distribution is part of the winding-up of Essa Pharma's operations following its planned transaction with XenoTherapeutics Inc., a non-profit biotechnology company, which will acquire all outstanding common shares.

Because the payout exceeds 25% of the company's share price, Nasdaq will implement due bill trading from August 19, 2025, through to August 25, 2025. During this period, shares will trade with an entitlement to the distribution.

Shareholders who sell during the due bill period will forfeit their right to the payment, while buyers in the same period will receive it. Due bill settlement will be handled by brokers, and Essa Pharma will not be responsible for processing these transactions.

Investors are advised to consult their brokers to fully understand Nasdaq's due bill procedures before trading during this period.